Who is sponsoring NCT05518136?

NCT05518136 is sponsored by Gejingwa Zhao.

What drugs are being tested in NCT05518136?

Interventions in NCT05518136: exercise-guidance on rehab APP.

What condition does NCT05518136 study?

NCT05518136 studies Congenital Heart Disease in Children, Infant Development, Infant Conditions, Motor Neuropathy, Motor Delay, Cardiopulmonary.

Is NCT05518136 still recruiting?

NCT05518136 is currently completed. Last updated 26 August 2022.

Last reviewed 2022-08-26 · How we verify

NCT05518136

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluations of Cardiopulmonary Function and Motor Development of Congenital Heart Disease

Completed NA Last updated 26 August 2022

What this trial tests

NA trial testing exercise-guidance on rehab APP in Congenital Heart Disease in Children in 28 participants. Completed in 25 May 2022.

Timeline

10 April 2021

Primary endpoint
28 December 2021

25 May 2022

Quick facts

Lead sponsor	Gejingwa Zhao
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	supportive care
Enrollment	28
Start date	10 April 2021
Primary completion	28 December 2021
Estimated completion	25 May 2022
Sites	1 location across China

Drugs / interventions tested

exercise-guidance on rehab APP

Conditions studied

Congenital Heart Disease in Children — all drugs for Congenital Heart Disease in Children →
Infant Development — all drugs for Infant Development →
Infant Conditions — all drugs for Infant Conditions →
Motor Neuropathy — all drugs for Motor Neuropathy →

Sponsor

Gejingwa Zhao

Who can join

Adults 4 Months to 8 Months, any sex, with Congenital Heart Disease in Children or Infant Development. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this single-center, randomized controlled trial, patients (4-8 months) with CHD were randomly assigned to either a recovery group (home-based rehab exercise periodically) supervised by cellphone APP or to a control group. Left ventricular ejection fractions (LVEF), the rate of increase in heart rate (rHRI), and the rate of recovery heart rate (rHRR) were measured for representing cardiopulmonary capacity. The Alberta test and Neuro-intelligence Scale were used to evaluate their motor developmental outcomes. This study verified the feasibility of this rehab method and indicated that 6-month home-based exercise training can improve cardiopulmonary endurance and motor developmental level in infant CHD patients.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Cellphone application rehabilitation management and evaluations of cardiopulmonary function and motor development in infants with congenital heart disease: a pilot study.
Zhao GJ, Li ZQ, Ma Y, Zhu YB, et al · · 2023 · PMID 37285015 · DOI 10.1007/s12519-023-00734-6

Verify or expand the search:

Other recruiting trials for Congenital Heart Disease in Children

Currently open trials in the same condition.

NCT07029230 — Blood Based Assessment of sST2, Taken During and After Surgery, for Pediatric Patients With Heart Defects to Predict Hea · recruiting
NCT07414251 — Evaluation of Preoperative Preparation in Children Undergoing Cardiac Surgery or Catheterization · recruiting
NCT06383546 — Artificial Intelligence-enabled ECG Detection of Congenital Heart Disease in Children: a Novel Diagnostic Tool · recruiting
NCT05647161 — BAX602 in Preventing the Adhesion Around Great Cardiac Vessels in Pediatric Patients With Congenital Heart Disease Under · NA · active not recruiting
NCT05268094 — Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial) · NA · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05518136 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Gejingwa Zhao
Last refreshed: 26 August 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05518136.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing